Back to top

Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness

Read MoreHide Full Article

Henry Schein, Inc. (HSIC - Free Report) has recently teamed up with Integrated Medical Foundation (IMF) and LUGPA, an association of independent urology group practices, to raise awareness on prostate cancer. More specifically, Henry Schein’s global corporate social responsibility program — Henry Schein Cares — will work on this matter.

Per Henry Schein, it will support IMF and LUGPA with a series of communication efforts to increase awareness among practitioners and public about the importance of early detection of prostate cancer. According to them, it has been widely accepted how early detection of prostate cancer can greatly enhance a patient’s chances of recovering from the disease.

We believe, the company’s move is well-timed taking into consideration the frequency rate at which prostate cancer is growing. The National Cancer Institute estimates that approximately one in nine men will be diagnosed with the disease in their lifetime. Per the American Cancer Society, more than 160,000 men are expected to be diagnosed with prostate cancer and more than 26,000 men may succumb to the disease in 2017.

Though Henry Schein is yet to make a foray into the world of cancer research, it has already come up with several awareness drives of late. Only last month, the company announced to offer its dental, animal health and medical customers an opportunity to join in the fight against cancer.

The proposal will be open from from September through December. By purchasing a range of pink products, customers can support the company’s Practice Pink program, an initiative designed to increase awareness and back the cure for breast cancer as well as other cancer therapies.

Over the past three months, Henry Schein has underperformed the broader industry. The stock has lost 5.7% compared with the the broader industry’s 1.7% decline.

Zacks Rank & Key Picks

Henry Schein carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 21.6% over the last six months.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 2.9% over the last six months.


(We are reissuing this article to correct a mistake. The original article, issued September 5, 2017, should no longer be relied upon.)

 

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>



More from Zacks Analyst Blog

You May Like